TARGETING THE CD6-ALCAM T CELL COSTIMULATORY PATHWAY AFTER ALLOGENEIC CELL TRANSPLANTATION FOR ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) TREATMENT USING ANTI-CD6 MONOCLONAL ANTIBODY ITOLIZUMAB

被引：0
|
作者：
Rambaldi, B. [1 ,2 ,3 ]
Kim, H. T. [4 ]
Arihara, Y. [1 ,2 ,5 ]
Asano, T. [1 ,2 ,6 ]
Reynolds, C. [1 ,2 ]
Manter, M. [1 ,2 ]
Halpern, M. [1 ,2 ]
Weber, A. [1 ,2 ]
Koreth, J. [1 ,2 ]
Cutler, C. [1 ,2 ]
Gooptu, M. [1 ,2 ]
Nikiforow, S. [1 ,2 ]
Ho, V. T. [1 ,2 ]
Antin, J. H. [1 ,2 ]
Romee, R. [1 ,2 ]
Ampudia, J. [7 ]
Ng, C. [7 ]
Connelly, S. [7 ]
Soiffer, R. J. [1 ,2 ]
Ritz, J. [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Milao Bicocca, PhD Program Translat & Mol Med DIMET, Milan, Italy
[4] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA
[5] Sapporo Med Univ, Dept Med Oncol, Sapporo, Hokkaido, Japan
[6] Himeji Red Cross Hosp, Dept Hematol & Oncol, Himeji, Hyogo, Japan
[7] Equillium, San Diego, CA USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C70
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [21] MONOCLONAL ANTI-T-CELL (T12) ANTIBODY TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN SEVERE COMBINED IMMUNODEFICIENCY - TARGETING OF ANTIBODY AND ACTIVATION OF COMPLEMENT ON CD8+ CYTOTOXIC T-CELL SURFACES
    BLOMQUIST, MD
    BOGGARDS, M
    HANSON, ICG
    ROSENBLATT, HM
    POLLACK, MS
    HAWKINS, E
    RITZ, J
    SHEARER, WT
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 87 (05) : 1029 - 1033
  • [22] Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab
    Bacigalupo, Andrea
    Angelucci, Emanuele
    Raiola, Anna Maria
    Varaldo, Riccardo
    Di Grazia, Carmen
    Gualandi, Francesca
    Benedetti, Edoardo
    Risitano, Antonio
    Musso, Maurizio
    Zallio, Francesco
    Ciceri, Fabio
    Chiusolo, Patrizia
    Sica, Simona
    Rambaldi, Alessandro
    Bonifazi, Francesca
    Parma, Matteo
    Martino, Massimo
    Onida, Francesco
    Iori, Anna Paola
    Selleri, Carmine
    Borghero, Carlo
    Bertaina, Alice
    Prezioso, Lucia
    Algeri, Mattia
    Locatelli, Franco
    BONE MARROW TRANSPLANTATION, 2020, 55 (08) : 1580 - 1587
  • [23] TREATMENT OF STEROID RESISTANT ACUTE GRAFT VERSUS HOST DISEASE WITH AN ANTI-CD26 MONOCLONAL ANTIBODY- BEGELOMAB
    Metafuni, E.
    Gualandi, F.
    Raiola, A. M.
    Varaldo, R.
    Di Grazia, C.
    Angelucci, E.
    Benedetti, E.
    Locatelli, F.
    Risitano, A.
    Musso, M.
    Zallio, F.
    Ciceri, F.
    Chiusolo, P.
    Rambaldi, A.
    Bonifazi, F.
    Parma, M.
    Martino, M.
    Onida, F.
    Iori, A. P.
    Selleri, C.
    Borghero, C.
    Bertaina, A.
    Van Lint, M. T.
    Bacigalupo, A.
    HAEMATOLOGICA, 2019, 104 : 45 - 45
  • [24] Anti-CD3 antibody HuM291 induces peripheral T cell apoptosis in patients with acute graft versus host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT).
    Frangoul, HA
    Lin, MT
    Carpenter, P
    Gooley, T
    Tso, JY
    Anasetti, C
    Hansen, JA
    BLOOD, 1998, 92 (10) : 448A - 448A
  • [25] Basiliximab in the treatment of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Ma, X
    Wu, DP
    Sun, AN
    BLOOD, 2005, 106 (11) : 426B - 426B
  • [26] IL17-producing CD161+ CCR6+T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation
    van der Waart, A. B.
    van der Velden, W. J. F. M.
    van Halteren, A. G. S.
    Leenders, M. J. L. G.
    Feuth, T.
    Blijlevens, N. M. A.
    van der Voort, R.
    Dolstra, H.
    IMMUNOLOGY, 2012, 137 : 610 - 610
  • [27] FINAL SAFETY AND EFFICACY RESULTS FROM EQUATE, AN OPEN-LABEL STUDY EVALUATING ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE
    Koreth, John
    Loren, Alison
    Nakamura, Ryotaro
    Waller, Edmund
    Pidala, Joseph
    Mielcarek, Marco
    Ng, Cherie
    Acevedo, Lisette
    Rothman, Joel
    Connelly, Stephen
    Fung, Maple
    Cutler, Corey
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 291 - 292
  • [28] Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation
    Arpinati, M
    Chirumbolo, G
    Urbini, B
    Bonifazi, F
    Bandini, G
    Saunthararajah, Y
    Zagnoli, A
    Stanzani, M
    Falcioni, S
    Perrone, G
    Tura, S
    Baccarani, M
    Rondelli, D
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 106 - 115
  • [29] CD8 T cell dose impacts acute graft-versus-host disease after reduced intensity conditioning (RIC) for allogeneic stem cell transplantation.
    Mohty, M
    Faucher, C
    Bagatini, S
    Bardou, VJ
    Bilger, K
    Chabannon, C
    Ladaique, P
    Vey, N
    Maraninchi, D
    Blaise, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 590S - 590S
  • [30] Balancing acute graft versus host disease (aGVHD) and survival after peripheral allogeneic stem cell transplantation (SCT) in hematological malignancies: A potential for graft engineering
    Saad, Ayman
    Almubarak, Mohammed
    Kanate, Abraham
    Cumpston, Aaron
    Watkins, Kathy
    Buckhalter, Regina
    Bunner, Pam
    Hobbs, Gerry
    Craig, Michael
    BLOOD, 2007, 110 (11) : 965A - 965A
12345